Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC

Clinical trial NCT06998719 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06998719
Sponsor: Bi Nan
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer Stage III Borderline Resectable Carcinoma

Start date: 2025-07-01
Primary completion: 2026-05-01
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.